CalciMedica, Inc.
CALCHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeCalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company carries a $11.2M market cap, placing it firmly in the micro-cap category. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Market Cap
$11.2M
Beta
1.11
P/E (TTM)
—
P/E (Fwd)
-0.44
EPS (TTM)
$-1.31
EPS (Fwd)
$-1.63
ROE
-399.5%
ROA
-81.8%
Cash
$8.2M
Total Debt
$6.7M
Free CF
-$13.5M
52W Change
-81.2%
Annual Financials
Cash vs Debt
Where CALC stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CALC finished 59.12% below its 150-day moving average ($1.81) and 66.21% below its 200-day moving average ($2.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CALC overbought or oversold?
At the July 15, 2026 close, CALC's RSI(14) was 47.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $8.2M in cash comfortably exceeding the $6.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$13.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -399.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CalciMedica, Inc.'s trajectory.